What Is Glucagon Like Peptide?

TLDR: In everyday health discussions, “glucagon-like peptide” usually means glucagon-like peptide-1, or GLP-1. It is a naturally occurring gut hormone released in connection with eating. GLP-1 helps coordinate insulin and glucagon signaling and can slow movement of food from the stomach. It is not glucagon, insulin, or a medication—although several medicines are designed to activate the GLP-1 receptor.

If you are asking what is glucagon like peptide, the short answer is that GLP-1 is one of the body’s chemical messengers. It belongs to a group called incretin hormones, which connect nutrient intake with the body’s response to glucose. The term can also refer to the related GLP-2 peptide, but popular discussions about diabetes, appetite, and weight usually mean GLP-1.

What is glucagon-like peptide-1?

Glucagon-like peptide-1 is a peptide hormone derived from a larger precursor molecule called proglucagon. Specialized intestinal cells known as L cells produce and release GLP-1, particularly in response to nutrients. Its classification as an incretin reflects its role in helping the body coordinate insulin secretion with food intake. A scientific review of GLP-1 physiology describes the hormone’s production and major physiological actions.

A peptide is a chain of amino acids that can act as a biological signal. Peptides have many unrelated jobs, so calling GLP-1 a peptide does not by itself tell us what it does. Readers who want the broader foundation can start with this plain-English guide to peptides.

GLP-1 is best understood as part of a communication system rather than as a substance that acts alone. After food reaches the digestive tract, GLP-1 contributes to signals exchanged among the gut, pancreas, and other tissues. Those signals help match the body’s response to the nutritional conditions at that moment.

Why is it called “glucagon-like”?

The name comes from molecular family history, not because GLP-1 does the same job as glucagon. Both molecules originate from proglucagon, a larger protein that can be cut and processed into different peptide products. Which products are made depends partly on the tissue and its processing enzymes.

That distinction explains an apparent contradiction: GLP-1 is structurally related to glucagon, yet the two can have contrasting effects on post-meal glucose regulation. Glucagon generally supports the availability of glucose in the bloodstream. GLP-1, by comparison, supports glucose-dependent insulin secretion and is associated with reduced glucagon secretion under relevant conditions.

“Glucagon-like” therefore means related to glucagon through a shared precursor and aspects of molecular structure. It does not mean identical to glucagon. Similar names among hormones often reflect how molecules were discovered or classified, not interchangeable biological effects.

What does GLP-1 do after a meal?

GLP-1 participates in several overlapping responses to food. Its most established actions concern insulin, glucagon, and the rate at which the stomach transfers its contents to the small intestine.

It supports glucose-dependent insulin secretion

GLP-1 can enhance insulin secretion when glucose is present. “Glucose-dependent” is an important qualifier: the signal is linked to the prevailing glucose environment rather than operating as a fixed command to release the same amount of insulin at all times. Experimental human work and physiological reviews support this insulin-promoting action.

This does not make GLP-1 another name for insulin. Insulin is a separate hormone with its own receptor and direct metabolic functions. The FDA explicitly distinguishes GLP-1 receptor agonist medicines from insulin.

It can reduce glucagon signaling

GLP-1 is also associated with suppression of glucagon secretion, especially in the context of post-meal glucose regulation. This complements its insulin-related action: instead of looking at either hormone in isolation, it is more accurate to view GLP-1 as helping coordinate the balance of signals after nutrients arrive.

It can slow gastric emptying

Gastric emptying is the movement of stomach contents into the small intestine. In an experimental human infusion study, GLP-1 slowed the emptying of solid food from the stomach. A slower transfer can change how quickly nutrients reach the intestine, although the finding should not be turned into a universal prediction about how every person will feel or respond to every GLP-1-related medicine.

GLP-1 is also commonly discussed in relation to appetite and fullness. That broader context helps explain public interest in the hormone, but a plausible physiological pathway is not enough to establish the benefits, risks, or expected results of a particular drug. Those questions require evidence for the specific medicine, population, outcome, and duration.

Natural GLP-1 and GLP-1 medicines are not the same thing

The body’s own GLP-1 is an endogenous hormone, meaning it is produced within the body. A GLP-1 receptor agonist is a medicine engineered to activate the receptor that responds to GLP-1. The FDA describes this drug class as mimicking a natural hormone made in the intestine.

Sharing a receptor does not make the natural hormone and every medicine interchangeable. Drug molecules can differ in structure, duration of action, approved indication, formulation, evidence base, and safety information. Results reported for one drug should not automatically be assigned to another, and findings about native GLP-1 physiology do not establish the clinical effects of a pharmaceutical product.

Term	What it refers to	Key distinction
GLP-1	A proglucagon-derived hormone released by intestinal L cells	The body’s natural signaling molecule
Glucagon	A related hormone derived from the same precursor	Not the same hormone and does not have the same physiological role
Insulin	A separate hormone involved in glucose regulation	GLP-1 can support its secretion, but GLP-1 is not insulin
GLP-1 receptor agonist	A medicine that activates the GLP-1 receptor	Drug effects and risks depend on the specific product
GLP-2	Another proglucagon-derived peptide	Related to GLP-1 but biologically and clinically distinct

Where does tirzepatide fit?

Not every medicine discussed alongside GLP-1 is GLP-1-only. Tirzepatide acts at both the glucose-dependent insulinotropic polypeptide receptor—usually shortened to GIP—and the GLP-1 receptor. The FDA therefore describes it as a dual GIP/GLP-1 receptor agonist.

That terminology matters when interpreting headlines or comparing research. Evidence about a dual-receptor medicine cannot be treated as evidence about GLP-1 signaling alone. Likewise, comparisons between separate clinical trials are indirect unless participants were randomized to the medicines within a genuine head-to-head study.

What is the difference between GLP-1 and GLP-2?

GLP-1 and GLP-2 are related peptides produced from proglucagon, but they are not alternative names for the same molecule. Tissue-specific processing of proglucagon produces different peptide products with different receptors and functions.

For a concrete clinical distinction, teduglutide is a GLP-2 analog. Its FDA labeling covers specified patients with short bowel syndrome who depend on parenteral support. That is a very different context from the glucose-related discussions that usually surround GLP-1. The existence of a GLP-2 medicine does not make GLP-2 a version of a GLP-1 receptor agonist.

A simple framework for interpreting GLP-1 claims

When a headline mentions GLP-1, first identify what is actually being discussed. This prevents evidence about normal physiology, one experimental drug, or one approved medicine from being blended into a single broad claim.

Identify the subject: Is the claim about the body’s natural GLP-1, an approved medicine, an investigational drug, or another product category?
Check the evidence level: Is the result from cells, animals, a human infusion experiment, an observational study, or a randomized clinical trial?
Name the outcome: Did researchers measure hormone concentrations, gastric emptying, blood glucose, body weight, symptoms, or a clinical health outcome?
Check the population and duration: A short experiment in healthy volunteers answers a different question from a long clinical trial in people with a diagnosed condition.
Keep molecules separate: Do not transfer results among GLP-1-only drugs, dual-receptor drugs, natural GLP-1, and GLP-2 analogs.

The same discipline applies to safety. “Peptide” is a molecular category, not a class-wide assurance of safety. Approved medicines, compounded products, investigational compounds, and research-use-only materials have different oversight and evidence. The broader guide Are Peptides Safe? explains why safety must be assessed product by product.

Frequently asked questions

Is GLP-1 a hormone or a medication?

GLP-1 itself is a naturally occurring hormone. GLP-1 receptor agonists are medications designed to activate its receptor. People often use “GLP-1” informally to describe the drug class, but keeping the hormone and medicines separate makes scientific and safety claims easier to interpret.

Where is GLP-1 made?

GLP-1 is produced from proglucagon in specialized intestinal cells called L cells. Processing of the proglucagon precursor varies by tissue, which is why one precursor can give rise to several related but distinct peptides.

Is GLP-1 the same as insulin?

No. GLP-1 can support insulin secretion in a glucose-dependent manner, but insulin is a separate hormone. GLP-1 receptor agonist medicines are also not insulin.

Is GLP-1 the same as glucagon?

No. GLP-1 and glucagon are related because they come from the proglucagon precursor, but they are distinct hormones with different actions. The “glucagon-like” name signals a molecular relationship rather than identical function.

Are all medicines called GLP-1 drugs equivalent?

No. Medicines that activate the GLP-1 receptor may differ in molecular design, approved uses, duration of action, clinical evidence, contraindications, warnings, and adverse effects. Some medicines, including tirzepatide, act at more than one receptor. Current prescribing information is necessary for medicine-specific conclusions.

The bottom line

Glucagon-like peptide most commonly refers to GLP-1: a proglucagon-derived gut hormone that helps coordinate the response to food. It supports glucose-dependent insulin secretion, can suppress glucagon secretion, and can slow gastric emptying. The name reflects its relationship to glucagon, not an identical function.

The most useful next step when reading a GLP-1 claim is to ask whether it concerns the natural hormone or a specific medicine. From there, check the study population, measured outcome, duration, and exact molecule. That distinction prevents basic physiology from being mistaken for proof that every GLP-1-related product has the same benefits or risks.